Back to search results

Study of ABBV-932 for Generalized Anxiety Disorder

This study is looking at an investigational medicine called ABBV-932 for adults with Generalized Anxiety Disorder (GAD). GAD is a condition where you feel excessive worry and anxiety. Many people with GAD take antidepressant therapies (ADTs), but sometimes these don't fully help. This study will see how safe and effective ABBV-932 is when added to your current ADT if your GAD symptoms haven't improved enough. You would be randomly assigned to receive either ABBV-932 or a placebo (an inactive capsule) along with your ADT. The study will measure side effects and changes in your anxiety symptoms over about 6 to 10 weeks. About 315 adults will participate across the United States and Puerto Rico.

Study design
This is an interventional study where participants are randomly assigned to receive either ABBV-932 or a placebo, in addition to their antidepressant therapy. There is a 1 in 3 chance of receiving the placebo.
What's involved
Participants will take oral capsules (either ABBV-932 or placebo) in addition to their current antidepressant therapy for up to approximately 10 weeks. The study will measure side effects and changes in anxiety symptoms.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes for up to approximately 10 weeks, with anxiety symptom changes specifically looked at up to about 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06846320

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Recruiting
PHASE2Ages 18–65InterventionalTreatment
AbbVie
~315 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:ABBV-932Placebo for ABBV-932Antidepressant Therapy (ADT)

At a glance

Recruiting sites
50 of 52 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to approximately 10 weeks
+1 more outcome measured

Conditions

Generalized Anxiety Disorder (GAD)

Explore related trials

Generalized Anxiety Disorder

Where it's being run

52 sites across 23 states
California9
Florida6
Texas5
Missouri3
Ohio3
Puerto Rico3
Arizona2
Georgia2

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).
Currently taking protocol-specified antidepressant therapies (ADT) for GAD with an inadequate response to an adequate dose (per label) and duration (\>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score \>= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) \>= 4.

Exclusion

Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score \>= 20.
New diagnosis or exacerbation of major depression in the last 6 months.

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to approximately 10 weeks

    An AE is defined as any untoward medical occurrence in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

  • Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total ScoreUp to approximately 6 weeks

    The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.